Imaging hypoxia in gliomas

Hypoxia plays a central role in tumour development, angiogenesis, growth and resistance to treatment. Owing to constant developments in medical imaging technology, significant advances have been made towards in vitro and in vivo imaging of hypoxia in a variety of tumours, including gliomas of the ce...

Full description

Saved in:
Bibliographic Details
Published in:British journal of radiology 2011-12, Vol.84 Spec No 2 (special_issue_2), p.S145-S158
Main Authors: Mendichovszky, I, Jackson, A
Format: Article
Language:English
Subjects:
Angiogenesis
Animals
Brain Neoplasms - blood supply
Brain Neoplasms - diagnosis
Brain tumors
Central nervous system
Contrast Media
Development
Functional magnetic resonance imaging
Glioma
Glioma - blood supply
Glioma - diagnosis
Humans
Hypoxia
Hypoxia - diagnosis
Magnetic Resonance Angiography - methods
Magnetic resonance imaging
Magnetic Resonance Imaging - methods
Manganese
Metronidazole
Microelectrodes
Positron-Emission Tomography - methods
Radiopharmaceuticals
Reviews
Spectroscopy
Tracers
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hypoxia plays a central role in tumour development, angiogenesis, growth and resistance to treatment. Owing to constant developments in medical imaging technology, significant advances have been made towards in vitro and in vivo imaging of hypoxia in a variety of tumours, including gliomas of the central nervous system. The aim of this article is to review the literature on imaging approaches currently available for measuring hypoxia in human gliomas and provide an insight into recent advances and future directions in this field. After a brief overview of hypoxia and its importance in gliomas, several methods of measuring hypoxia will be presented. These range from invasive monitoring by Eppendorf polarographic O(2) microelectrodes, positron electron tomography (PET) tracers based on 2-nitroimidazole compounds [(18)F-labelled fluoro-misonidazole ((18)F-MISO) or 1-(2-[((18))F]fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole (FRP-170)], (64)Cu-ATSM Cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) or (99m)Tc- and (68)Ga-labelled metronidazole (MN) agents to advanced MRI methods, such as blood oxygenation level dependent (BOLD) MRI, oxygen-enhanced MRI, diffusion-weighted MRI (DWI-MRI), dynamic contrast-enhanced MRI (DCE-MRI) and (1)H-magnetic resonance spectroscopy.
ISSN:0007-1285
1748-880X
DOI:10.1259/bjr/82292521